Authors

Latest:

Dr Rijneveld on the Addition of Blinatumomab to Prephase and Consolidation Therapy in B-ALL

Anita Rijneveld, MD, discusses outcomes with the addition of blinatumomab to prephase and consolidation therapy for patients with adult B-cell acute lymphoblastic leukemia.

Rondell Graham, MBBS

Latest:

Dr. Graham on the Role of the Pathologist in Biomarker Testing in Breast and GI Cancers

Rondell P. Graham, MBBS, discusses the role of the pathologist in biomarker testing for patients with breast and gastrointestinal cancers.

Sarah Sammons, MD, Duke Cancer Institute

Latest:

Targeting the PI3K Pathway in HR+/HER2- MBC

The rationale for investigating the role of therapies that target the PI3K pathway in HR+/HER2- metastatic breast cancer.

Russell Langan, MD

Latest:

RWJBarnabas Health Pioneers Innovative Pancreatic Cyst Surveillance Program

The incidental identification of pancreatic cysts has become more common with the increasing use of imaging modalities in clinical practice.

Rachel Riechelmann, MD, PhD

Rachel Riechelmann, MD, PhD, is a medical oncologist, postgraduate professor, and clinical scientist specialized in neuroendocrine tumors (NET) and colorectal/anal cancers

Latest:

Dr Riechelmann on the Management of Refractory Carcinoid Syndrome in Functional GI NETs

Rachel Riechelmann, MD, PhD, discusses clinical guidance for the management of refractory carcinoid syndrome in functional GI neuroendocrine tumors.

Mark G. Kris, MD

Latest:

Dr. Kris on Immunotherapy in NSCLC Without Driver Mutations

Mark G. Kris, MD, discusses the role of immunotherapy in patients with non–small cell lung cancer without driver mutations.

Koral Shah, MD

Koral Shah, MD, is a fellow in Hematology & Medical Oncology at City of Hope in Duarte, California.

Latest:

Dr Shah on Disparities in Worldwide Bladder Cancer Trial Availability

Koral Shah, MD, details the rationale of evaluating worldwide disparities in bladder cancer clinical trial availability.

Shipra Gandhi, MD

Latest:

Insights From SABCS 2024 and Future Directions in Breast Cancer

Dr. Gandhi and Dr. Clifton explore clinical decision-making and sequencing for selective estrogen receptor degraders (SERDs), antibody-drug conjugates (ADCs), and other targeted therapies in hormone receptor–positive/HER2-negative (HR+/HER2–) metastatic breast cancer (mBC), balancing efficacy, safety, and patient characteristics, while highlighting promising data from the 2024 San Antonio Breast Cancer Symposium (SABCS) and the role of precision medicine in improving outcomes and patient experiences.

Stergios J. Moschos, MD

Latest:

Dr Moschos on Treatment Strategies With Adoptive T-Cell Therapy in Melanoma

Stergios J. Moschos, MD, discusses how the use of bridging therapy can enhance the efficacy of adoptive T-cell therapies for patients with melanoma.

Hiromichi Shirasu, MD

Latest:

Dr. Shirasu on the Clinical Implications of ctDNA in CRC

Hiromichi Shirasu, MD, discusses the clinical implications of the GALAXY trial as part of the CIRCULATE-Japan project, which is investigating circulating tumor DNA status in patients with resectable colorectal cancer.

Kevin M. Kalinsky, MD, Columbia University Medical Center

Latest:

Dr. Kalinsky on Therapeutic Options Beyond Chemotherapy in High-Risk Breast Cancer

Kevin Kalinsky, MD, MS, discusses treatment options beyond chemotherapy in patients with high-risk breast cancer.

Kerry Savage, MD, MSc

Kerry Savage, MD, MSc, is a medical oncologist at BC Cancer and a professor of medicine at the University of British Columbia.

Latest:

Decoding T-Cell Lymphomas: An Approach to Diagnosis & Treatment

Kerry Savage, MD, MSc, and Neha Mehta-Shah, MD, discuss approaches to diagnosing and treating T-cell lymphomas.

Craig Jones, MBChB

Latest:

Dr Jones on Clinical Fracture Incidence in mHSPC

Craig Jones, MBChB, discusses findings from an analysis of fracture incidence in patients with metastatic hormone-sensitive prostate cancer from the phase 2/3 STAMPEDE trial platform protocol.

Arnon Kater, MD, PhD

Latest:

Emerging Agents and Future Strategies in Relapsed/Refractory CLL

Panelists discuss the role of non-covalent BTKis in this setting and available supporting data (high level).

Rebecca L. Porter, MD, PhD

Latest:

Dr Porter on Mirvetuximab Soravtansine Plus Pembrolizumab in FRα+ pMMR/MSS Endometrial Cancer

Rebecca L. Porter, MD, PhD, discusses the evaluation of mirvetuximab soravtansine plus pembrolizumab in FRα-positive, pMMR/MSS endometrial cancer.

Pietro Scilipoti, MD

Pietro Scilipoti, MD, is a urologist at IRCCS San Raffaele Hospital in Italy.

Latest:

Dr Scilipoti on the Value of Life Expectancy Assessments to Guide Prostate Cancer Treatment Strategies

Pietro Scilipoti, MD, discusses the need for better life expectancy assessment to guide prostate cancer treatment strategies.

Narjust Florez (Duma), MD

Latest:

Dana-Farber Cancer Institute and the Florez Laboratory Set to Launch Innovative Pregnancy and Lung Cancer Registry

The Florez Lab at Dana-Farber Cancer Institute is launching the innovative International Pregnancy and Lung Cancer Registry.

Nathalie Albert, MD

Latest:

Q&A: Final Questions on Glioblastoma and Neuroimaging

Nathalie Albert, MD, and Matthias Preusser, MD, address audience questions and share their insights on promising and anticipated advancements in neuroimaging techniques, highlighting the potential impact of these emerging strategies on the diagnosis, monitoring, and treatment of glioblastoma.

Kevin Harrington, MBBS, MRCP, FRCR, FRCP, PhD, DIC

Latest:

Future Considerations for the Treatment of R/M HPV-Positive HNSCC

Panelists discuss how emerging areas in recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) research include novel immunotherapy combinations, biomarker development for treatment selection, targeted therapies against new molecular pathways, and strategies to overcome resistance to existing treatments.

Lora Markley

Latest:

Quality Over Quantity: What Concierge Medicine Can Offer to Patients With Cancer and Employers

The current health care economy has driven many employers to self-funding models to offer affordable health care coverage to employees.